"Angiogenesis Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents and endogenous substances that antagonize or inhibit the development of new blood vessels.
| Descriptor ID |
D020533
|
| MeSH Number(s) |
D27.505.696.377.077.099 D27.505.696.377.450.100 D27.505.954.248.025
|
| Concept/Terms |
Angiogenesis Inhibitors- Angiogenesis Inhibitors
- Neovascularization Inhibitors
- Angiogenic Antagonists
- Angiogenic Inhibitors
- Angiostatic Agents
- Agents, Angiostatic
- Antagonists, Angiogenic
- Anti-Angiogenetic Agents
- Agents, Anti-Angiogenetic
- Anti Angiogenetic Agents
- Anti-Angiogenic Drugs
- Anti Angiogenic Drugs
- Drugs, Anti-Angiogenic
- Antiangiogenic Agents
- Agents, Antiangiogenic
- Inhibitors, Angiogenesis
- Inhibitors, Angiogenetic
- Inhibitors, Angiogenic
- Inhibitors, Neovascularization
- Angiogenetic Antagonists
- Antagonists, Angiogenetic
- Angiogenetic Inhibitors
Anti-Angiogenesis Effect- Anti-Angiogenesis Effect
- Anti Angiogenesis Effect
- Effect, Anti-Angiogenesis
- Antiangiogenesis Effect
- Effect, Antiangiogenesis
- Antiangiogenesis Effects
- Effects, Antiangiogenesis
- Anti-Angiogenesis Effects
- Anti Angiogenesis Effects
- Effects, Anti-Angiogenesis
|
Below are MeSH descriptors whose meaning is more general than "Angiogenesis Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Angiogenesis Inhibitors".
This graph shows the total number of publications written about "Angiogenesis Inhibitors" by people in this website by year, and whether "Angiogenesis Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 2 | 0 | 2 |
| 2000 | 2 | 1 | 3 |
| 2001 | 4 | 0 | 4 |
| 2002 | 7 | 2 | 9 |
| 2003 | 6 | 2 | 8 |
| 2004 | 5 | 5 | 10 |
| 2005 | 5 | 3 | 8 |
| 2006 | 3 | 3 | 6 |
| 2007 | 6 | 4 | 10 |
| 2008 | 8 | 4 | 12 |
| 2009 | 7 | 3 | 10 |
| 2010 | 12 | 2 | 14 |
| 2011 | 6 | 5 | 11 |
| 2012 | 12 | 6 | 18 |
| 2013 | 7 | 5 | 12 |
| 2014 | 11 | 3 | 14 |
| 2015 | 3 | 4 | 7 |
| 2016 | 8 | 3 | 11 |
| 2017 | 4 | 5 | 9 |
| 2018 | 6 | 2 | 8 |
| 2019 | 4 | 1 | 5 |
| 2020 | 5 | 1 | 6 |
| 2021 | 3 | 6 | 9 |
| 2022 | 0 | 4 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Angiogenesis Inhibitors" by people in Profiles.
-
Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma: The CANTATA Randomized Clinical Trial. JAMA Oncol. 2022 10 01; 8(10):1411-1418.
-
A Phase II Study of sEphB4-HSA in Metastatic Castration-Resistant Prostate Cancer. Clin Genitourin Cancer. 2022 12; 20(6):575-580.
-
Fluctuations in central foveal thickness and association with vision outcomes with anti-VEGF therapy for nAMD: HARBOR post hoc analysis. BMJ Open Ophthalmol. 2022; 7(1):e000957.
-
A Randomized, Double-Masked, Multicenter Trial of Topical Acrizanib (LHA510), a Tyrosine Kinase VEGF-Receptor Inhibitor, in Treatment-Experienced Subjects With Neovascular Age-Related Macular Degeneration. Am J Ophthalmol. 2022 07; 239:180-189.
-
Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients. Br J Cancer. 2022 02; 126(2):265-274.
-
Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2021 10; 22(10):1438-1447.
-
Gnotobiotic Operations and Assembly for Development of Germ-Free Animal Model of Laser-Induced Choroidal Neovascularization. Transl Vis Sci Technol. 2021 08 02; 10(9):14.
-
Neurodevelopmental outcomes following bevacizumab treatment for retinopathy of prematurity: a systematic review and meta-analysis. J Perinatol. 2021 09; 41(9):2377-2378.
-
Probabilistic Forecasting of Anti-VEGF Treatment Frequency in Neovascular Age-Related Macular Degeneration. Transl Vis Sci Technol. 2021 06 01; 10(7):30.
-
Plasma levels of angiopoietin-2, VEGF-A, and VCAM-1 as markers of bevacizumab-induced hypertension: CALGB 80303 and 90401 (Alliance). Angiogenesis. 2022 02; 25(1):47-55.